The evaluation of pulsatile GnRH or sequential human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with idiopathic hypogonadotropic hypogonadism

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-16009168

Enrollment

Unknown

Registered

2016-09-06

Start date

2014-03-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic hypogonadotropic hypogonadism

Interventions

GnRH group:Pulsatile GnRH therapy

HCG/HMG group:sequential HCG/HMG therapy

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: (1) IHH male patients above age 16 with desire for spermatogenesis; (2) absent of the secondary sexual characteristics or no development; (3) decreased serum T and gonadotrophin levels, and (4) normal anterior pituitary function with no lesion or mass on MRI of the hypothalamic-pituitary area; (5) Normal thyroid and adrenal function.

Exclusion criteria

Exclusion criteria: (1) the presence or history of cryptorchidism; (2) acquired hypogonadism; (3) the presence of sperm in the semen; (4) system diseases; (5) having received GnRH or HCG or testosterone replacement therapy one months prior to the study enrollment.

Design outcomes

Primary

Measure	Time frame
Proportion of patients present with sperm in the ejaculate;	—

Secondary

Measure	Time frame
penile length;time of spermatogenesis;testis volume;serum testosterone;side effects;	—

Countries

China

Contacts

Public ContactZhihong Liao

First Affiliated Hospital of Sun Yat-sen University

liaozhh@mail.sysu.edu.cn+86 18925106578

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026